Simplex Trading
VTGN icon

Simplex Trading’s VistaGen Therapeutics VTGN Stock Holding History

Simplex Trading’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23K Sell
14,295
-75,354
-84% -$45.5K ﹤0.01% 8411
2026
Q1 		$51.3K Buy
+89,649
New +$54.5K ﹤0.01% 5854
2025
Q3 		– Sell
-22,536
Closed -$67.3K – 10184
2025
Q2 		$45K Buy
22,536
+20,134
+838% +$45.7K ﹤0.01% 6035
2025
Q1 		$6K Sell
2,402
-191
-7% -$541 ﹤0.01% 7498
2024
Q4 		$7K Sell
2,593
-20,407
-89% -$57.4K ﹤0.01% 7458
2024
Q3 		$69K Buy
23,000
+5,893
+34% +$20.1K ﹤0.01% 5591
2024
Q2 		$59K Buy
+17,107
New +$74.1K ﹤0.01% 5920
2024
Q1 		– Sell
-12,371
Closed -$59.5K – 10016
2023
Q4 		$63K Buy
12,371
+9,907
+402% +$37.5K ﹤0.01% 5870
2023
Q3 		$12K Buy
2,464
+1,518
+160% +$6.74K ﹤0.01% 7074
2023
Q2 		$1K Buy
946
+456
+93% +$1.6K ﹤0.01% 8751
2023
Q1 		$1K Sell
490
-903
-65% -$4.74K ﹤0.01% 8791
2022
Q4 		$4K Sell
1,393
-13,915
-91% -$52.4K ﹤0.01% 8273
2022
Q3 		$69K Buy
15,308
+13,691
+847% +$136K ﹤0.01% 6014
2022
Q2 		$42K Buy
+1,617
New +$57.1K ﹤0.01% 6724

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Simplex Trading's VTGN Position: Q2 2026 in Review

Simplex Trading reduced its VistaGen Therapeutics (VTGN) stake by 84% in Q2 2026, selling an estimated $45.5K and leaving 14,295 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #8411.

Simplex Trading first reported a position in VTGN in Q2 2022 and has held it in 14 quarters since. The position peaked at $69K in Q3 2024. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Simplex Trading held 14,295 shares of VistaGen Therapeutics worth $3.23K as of Q2 2026.
  • Simplex Trading sold 75,354 VistaGen Therapeutics shares in Q2 2026, an estimated $45.5K.
  • VistaGen Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8411 holding.
  • Simplex Trading first reported a position in VistaGen Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Simplex Trading's VistaGen Therapeutics position peaked at $69K in Q3 2024.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.